Allon Therapeutics Inc.

Presenter: Gordon McCauley, President & CEO

Company Profile

Allon Therapeutics Inc. is a clinical-stage biotechnology company focused on developing the first drugs that impact the progression of neurodegenerative diseases. Allon's lead drug davunetide has demonstrated human efficacy in amnestic mild cognitive impairment, a precursor to Alzheimer's disease, and cognitive impairment associated schizophrenia. Allon is proceeding in advanced clinical trials in an orphan indication, Progressive Supranuclear Palsy (PSP), and will pursue the major markets, Alzheimer's disease and cognitive impairment associated schizophrenia, with a pharmaceutical partner. The Company is listed on the Toronto Stock Exchange under the trading symbol "NPC" (Neuro Protection Company) and based in Vancouver. For additional information please visit the Company's website: www.allontherapeutics.com.

Intellectual Property

Allon holds exclusive license to a broad and well-defined intellectual property portfolio consisting of 14 different families of 54 issued patents (including composition of matter) and 25+ pending.

Management Team

Gordon C. McCauley
President & CEO

Matthew J. Carlyle, CFA
Chief Financial Officer

Dr. J. Steven Whitaker
VP, Clinical Development & Chief Medical Officer

Dr. Bruce H. Morimoto
VP, Drug Development

Dr. Alistair J. Stewart
VP, Commercial Research

Presenter Bio

Gordon C. McCauley
President & CEO

Gordon McCauley was appointed President of Allon in 2004. Mr. McCauley is a co-founder, and the former President and COO of Neuro Discovery Inc., now NDI Capital. Prior to co-founding NDI, he led the successful growth and development of two Canadian healthcare companies. Outside of the healthcare industry, Mr. McCauley has been a senior sales and public affairs executive for a Canadian multinational energy company and served in a staff capacity to two Prime Ministers and former Ontario Premier David Peterson. Mr. McCauley serves on the Board of Hallmark Insurance, ACETECH, BIOTECanada, the Biotechnology Industry Organization (BIO), Washington, D.C., and LifeSciences British Columbia.

Contact

Allon Therapeutics Inc.
506-1168 Hamilton Street
Vancouver
British Columbia, Canada
V6B 2S2

ph: 604-736-0634
fx: 604-736-1616

www.allontherapeutics.com
gmccauley@allontherapeutics.com